Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase

Pacira BioSciences, Inc.

2024-Q1 EPS reported $0.19 revenue$167,117,000

GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.
Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.
Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.
Board authorizes $150M share repurchase program through Dec 2026.
FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pacira BioSciences, Inc. reported first quarter ended March 31, 2024 results: revenue $167.1 million, net income $9.0 million, EPS $0.19 per share (basic and diluted).

Period: first quarter ended March 31, 2024
Revenue: $167.1 million
Net income: $9.0 million
EPS: $0.19 per share (basic and diluted)
Result: reported results

Exact text from the filing

First Quarter 2024 Financial Highlights • Total revenues of $167.1 million • Net product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera° • Net income of $9.0 million, or $0.19 per share (basic and diluted)

View on SEC.gov

1435 earnings releases filed in the last 30 days. Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-24-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.